JAK1 Antibody - #AF5012

(10)   (12)  
Product: JAK1 Antibody
Catalog: AF5012
Description: Rabbit polyclonal antibody to JAK1
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 130kDa; 133kD(Calculated).
Uniprot: P23458
RRID: AB_2834933

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(100%), Bovine(100%), Horse(91%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(91%)
Clonality:
Polyclonal
Specificity:
JAK1 Antibody detects endogenous levels of total JAK1.
RRID:
AB_2834933
Cite Format: Affinity Biosciences Cat# AF5012, RRID:AB_2834933.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

JAK 1; JAK 1A; JAK 1B; JAK-1; JAK1; JAK1_HUMAN; JAK1A; JAK1B; Janus kinase 1 (a protein tyrosine kinase); Janus kinase 1; JTK3; Tyrosine protein kinase JAK 1; Tyrosine protein kinase JAK1; Tyrosine-protein kinase JAK1;

Immunogens

Immunogen:
Uniprot:

P23458(JAK1_HUMAN) >>Visit HPA database.

Gene(ID):
JAK1(3716)
Expression:
P23458 JAK1_HUMAN:

Expressed at higher levels in primary colon tumors than in normal colon tissue. The expression level in metastatic colon tumors is comparable to the expression level in normal colon tissue.

Description:
Janus kinase 1 (JAK1), is a member of a new class of protein-tyrosine kinases (PTK) characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain.
Sequence:
MQYLNIKEDCNAMAFCAKMRSSKKTEVNLEAPEPGVEVIFYLSDREPLRLGSGEYTAEELCIRAAQACRISPLCHNLFALYDENTKLWYAPNRTITVDDKMSLRLHYRMRFYFTNWHGTNDNEQSVWRHSPKKQKNGYEKKKIPDATPLLDASSLEYLFAQGQYDLVKCLAPIRDPKTEQDGHDIENECLGMAVLAISHYAMMKKMQLPELPKDISYKRYIPETLNKSIRQRNLLTRMRINNVFKDFLKEFNNKTICDSSVSTHDLKVKYLATLETLTKHYGAEIFETSMLLISSENEMNWFHSNDGGNVLYYEVMVTGNLGIQWRHKPNVVSVEKEKNKLKRKKLENKHKKDEEKNKIREEWNNFSYFPEITHIVIKESVVSINKQDNKKMELKLSSHEEALSFVSLVDGYFRLTADAHHYLCTDVAPPLIVHNIQNGCHGPICTEYAINKLRQEGSEEGMYVLRWSCTDFDNILMTVTCFEKSEQVQGAQKQFKNFQIEVQKGRYSLHGSDRSFPSLGDLMSHLKKQILRTDNISFMLKRCCQPKPREISNLLVATKKAQEWQPVYPMSQLSFDRILKKDLVQGEHLGRGTRTHIYSGTLMDYKDDEGTSEEKKIKVILKVLDPSHRDISLAFFEAASMMRQVSHKHIVYLYGVCVRDVENIMVEEFVEGGPLDLFMHRKSDVLTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNLLLAREGIDSECGPFIKLSDPGIPITVLSRQECIERIPWIAPECVEDSKNLSVAADKWSFGTTLWEICYNGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRCMNYDPNQRPFFRAIMRDINKLEEQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Dog
100
Chicken
100
Rabbit
100
Horse
91
Xenopus
91
Zebrafish
55
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P23458 As Substrate

Site PTM Type Enzyme
Phosphorylation
M1 Acetylation
Y3 Phosphorylation
K100 Ubiquitination
T119 Phosphorylation
S125 Phosphorylation
K142 Ubiquitination
K213 Ubiquitination
S216 Phosphorylation
Y217 Phosphorylation
Y220 Phosphorylation
K227 Ubiquitination
S228 Phosphorylation
K245 Ubiquitination
K249 Ubiquitination
K254 Ubiquitination
K267 Ubiquitination
K269 Acetylation
K269 Ubiquitination
S333 Phosphorylation
K386 Ubiquitination
Y412 Phosphorylation
K493 Ubiquitination
K496 Ubiquitination
K504 Ubiquitination
Y507 Phosphorylation
S515 Phosphorylation
S518 Phosphorylation
S524 Phosphorylation
K541 Ubiquitination
K559 Ubiquitination
Y568 Phosphorylation
S574 Phosphorylation
K581 Ubiquitination
Y605 Phosphorylation
K606 Ubiquitination
T687 Phosphorylation
T688 Phosphorylation
K691 Ubiquitination
K696 Ubiquitination
K708 Ubiquitination
K718 Ubiquitination
K736 Ubiquitination
S738 Phosphorylation
K768 Ubiquitination
K802 Ubiquitination
K847 Ubiquitination
S857 Phosphorylation
K860 Ubiquitination
K872 Ubiquitination
K888 Ubiquitination
K908 Ubiquitination
S909 Phosphorylation
K911 Ubiquitination
K923 Ubiquitination
K924 Ubiquitination
K939 Ubiquitination
K941 Ubiquitination
Y967 Phosphorylation
K978 Ubiquitination
Y993 Phosphorylation
K1018 Ubiquitination
K1026 Ubiquitination
T1030 Phosphorylation
K1032 Ubiquitination
Y1034 Phosphorylation P52333 (JAK3) , P23458 (JAK1)
Y1035 Phosphorylation P23458 (JAK1) , P52333 (JAK3)
T1036 Phosphorylation
K1038 Ubiquitination
S1043 Phosphorylation
T1107 Phosphorylation
K1109 Acetylation
K1109 Ubiquitination
K1112 Acetylation
Y1125 Phosphorylation
K1130 Ubiquitination

PTMs - P23458 As Enzyme

Substrate Site Source
P14784 (IL2RB) Y364 Uniprot
P15260 (IFNGR1) Y457 Uniprot
P19525-1 (EIF2AK2) Y101 Uniprot
P19525-1 (EIF2AK2) Y293 Uniprot
P23458 (JAK1) Y1034 Uniprot
P23458 (JAK1) Y1035 Uniprot
P29597 (TYK2) Y1054 Uniprot
P29597 (TYK2) Y1055 Uniprot
P35568 (IRS1) Y612 Uniprot
P35568 (IRS1) Y632 Uniprot
P35568 (IRS1) Y662 Uniprot
P35568 (IRS1) Y732 Uniprot
P40763-2 (STAT3) Y704 Uniprot
P40763 (STAT3) Y705 Uniprot
P42224-2 (STAT1) Y701 Uniprot
P52630-3 (STAT2) Y690 Uniprot
Q13651 (IL10RA) Y446 Uniprot
Q13651 (IL10RA) Y496 Uniprot
Q99683 (MAP3K5) Y718 Uniprot

Research Backgrounds

Function:

Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor as well as interleukin (IL)-10 receptor.

PTMs:

Autophosphorylated. Phosphorylated on tyrosine residues in response to interferon gamma signaling. Dephosphorylation of Tyr-1034 and Tyr-1035 by PTPN2 negatively regulates cytokine-mediated signaling.

Ubiquitinated by RNF125; leading to its degradation by the proteasome.

Subcellular Location:

Endomembrane system>Peripheral membrane protein.
Note: Wholly intracellular, possibly membrane associated.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed at higher levels in primary colon tumors than in normal colon tissue. The expression level in metastatic colon tumors is comparable to the expression level in normal colon tissue.

Subunit Structure:

Interacts with IL31RA. Interacts with IFNAR2. Interacts with IFNGR1. Interacts with JAKMIP1. Interacts with SHB. Interacts (via N-terminus) with IL2RB and IL10RA (via its cytoplasmic domain). Interacts with FER (By similarity).

Family&Domains:

Possesses two phosphotransferase domains. The second one probably contains the catalytic domain, while the presence of slight differences suggest a different role for domain 1.

The FERM domain mediates interaction with JAKMIP1.

Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.

Research Fields

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Th1 and Th2 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

References

1). Aligned electrospun poly(l-lactide) nanofibers facilitate wound healing by inhibiting macrophage M1 polarization via the JAK-STAT and NF-κB pathways. JOURNAL OF NANOBIOTECHNOLOGY, 2022 (PubMed: 35883095) [IF=10.2]

Application: WB    Species: Mice    Sample:

Fig. 3 The underlying mechanism by which aligned fibers affected macrophage polarization. A Venn diagram showing differentially expressed genes. B KEGG pathway analysis between the A20 and R20 groups. C Heatmap of differentially expressed genes among the three groups. D Heatmap of macrophage polarization-related genes between the A20 and R20 groups. E Volcano diagram of differentially expressed genes. F Western blot analysis of the NF-κB signaling pathway. G Immunofluorescence staining showing the nuclear translocation of NF-κB p65. The nucleus is stained blue, and NF-κB p65 protein is stained red. H Western blot images and semiquantitative analysis of the JAK-STAT signaling pathway (*p < 0.05, **p < 0.01, n = 3)
2). Effects of Cyhalofop-butyl on the Developmental Toxicity and Immunotoxicity in Zebrafish (Danio rerio). Chemosphere, 2021 (PubMed: 33297003) [IF=8.8]

Application: WB    Species: Fish    Sample: zebrafish larvae

Fig. 5. Cyhalofop-butyl up-regulated the expression of the JAK-STAT signaling pathway related genes in zebrafish larvae. (A) At 96 hpf, the mRNA expression patterns of JAK1, STAT3, SOCS3b, TNF-a, CXCL-C1C, IL-6 and IL-1b in zebrafish larvae exposed to 0.5 mg/L cyhalofop-butyl (n ¼ 3, mean ± S.E., *p < 0.05,**p < 0.01,***p < 0.001). (B) The protein expression patterns of JAK1, STAT3 and apoptosis related genes in zebrafish larvae exposed to 0.5 mg/L cyhalofop-butyl. GAPDH is an internal reference gene. (C) The number of neutrophils in the tail of Tg (lyz: DsRed) transgenic zebrafish treated with ruxolitinib. The white rectangle represents the CHT region in the tail of zebrafish. (D) The statistical chart of neutrophils in Fig. 5C (N ¼ 20, **p < 0.01, ***p < 0.001). CyB: cyhalofop-butyl. Data represent the analysis results of one-way ANOVAeDunnett test. Error bars, mean ± S.E.
3). CTLA4Ig/VISTAIg combination therapy selectively induces CD4+ T cell-mediated immune tolerance by targeting the SOCS1 signaling pathway in porcine islet xenotransplantation. IMMUNOLOGY, 2022 (PubMed: 35263451) [IF=6.4]
4). Monotropein inhibits colitis associated cancer through VDR/JAK1/STAT1 regulation of macrophage polarization. International Immunopharmacology, 2023 (PubMed: 37633235) [IF=5.6]
5). TRIM65 knockout inhibits the development of HCC by polarization tumor-associated macrophages towards M1 phenotype via JAK1/STAT1 signaling pathway. International immunopharmacology, 2024 (PubMed: 38218012) [IF=5.6]
6). BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo. MOLECULAR CARCINOGENESIS, 2017 (PubMed: 27770580) [IF=4.6]

Application: WB    Species: human    Sample: HepG2

Figure 6. Effect of BCL2L10 on its downstream gene expression profiles of human cancer pathway in HepG2 cells. (A) By human cancer pathway PCR array, ectopic expression of BCL2L10 up- or down-regulated several genes related to tumor proliferation, apoptosis, metastasis and angiogenesis. (B) Western blot was performed to confirm the downstream gene expression regulated by BCL2L10 in HepG2 cells. GAPDH was used as an internal control. (C) Schematic diagram of the molecular events for BCL2L10 function as a tumor suppressor through regulating cell cycle, proliferation, apoptosis metastasis and angiogenesis effectors.
7). Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Oncology Reports, 2018 (PubMed: 29328487) [IF=4.2]

Application: WB    Species: human    Sample: BxPC-3 and PANC‑1 cells

Figure 3.| The gemcitabine-erlotinib (E+G) combination group inhibits the activity of the JAK-STAT pathway, as well as the expression of downstream HIF‑1α, cyclin D1 and p53. (E) Phosphorylation levels of JAK1 (Tyr1022), JAK2 (Tyr221), JAK3(Tyr981) and STAT3 (Tyr701) in BxPC-3 and PANC‑1 cells were analyzed by western blotting, respectively.
8). CD163 protein inhibits lipopolysaccharide-induced macrophage transformation from M2 to M1 involved in disruption of the TWEAK-Fn14 interaction. Heliyon, 2024 (PubMed: 38148798) [IF=4.0]

Application: WB    Species: Human    Sample: macrophages

Fig. 4 CD163 blocks the interaction of TWEAK and Fn14 during the LPS-induced transformation of macrophages from M2 to M1. Co-immunoprecipitation was performed to understand the interaction between CD163 and TWEAK (A) and the interaction between Fn14 and TWEAK (B) in macrophages under indicated treatment. (C) The decreased CD163 protein on the surface of macrophages induced by LPS weakened the interaction between TWEAK and CD163 and strengthened the binding of TWEAK and Fn14, which activated the MAPK–NF-κB pathway and induced the transformation of macrophages from M2 to M1.
9). Curcumin prevents osteocyte apoptosis by inhibiting M1-type macrophage polarization in mice model of glucocorticoid-associated osteonecrosis of the femoral head. Journal of Orthopaedic Research®, 2020 (PubMed: 32009245) [IF=2.8]

Application: WB    Species: Mice    Sample: macrophages

Figure 5 A‐F, The expression of JAK1, p‐JAK1, JAK2, p‐JAK2, STAT1, and p‐STAT1 in macrophages within each group as determined by western blot analysis. G‐I, Quantitative analysis of the bands measured by gray value. The experiment was carried out a minimum of three times, and values are expressed as the mean ± SD. *P  < .05 and **P < .01 compared with MI. JAK, Janus kinase; STAT, signal transducer and activator of transcription [Color figure can be viewed at wileyonlinelibrary.com]
10). Scorpion venom polypeptide governs alveolar macrophage M1/M2 polarization to alleviate pulmonary fibrosis. Tissue and Cell, 2022 (PubMed: 36179453) [IF=2.6]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.